{"id":"pravastatin-valsartan-pravastatin-valsartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pravastatin is a statin that reduces LDL cholesterol by inhibiting the rate-limiting enzyme in cholesterol synthesis. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking vasoconstriction and aldosterone secretion. Together, they provide complementary cardiovascular protection by addressing dyslipidemia and hypertension simultaneously.","oneSentence":"Pravastatin inhibits HMG-CoA reductase to lower cholesterol, while valsartan blocks angiotensin II receptors to reduce blood pressure; the combination addresses both lipid and hypertension management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:04.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with dyslipidemia"},{"name":"Cardiovascular risk reduction in patients requiring both statin and ARB therapy"}]},"trialDetails":[{"nctId":"NCT06357104","phase":"PHASE4","title":"Detoxification From the Lipid Tract","status":"COMPLETED","sponsor":"Pachankis, Yang I., M.D.","startDate":"2024-02-26","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":1},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT00738972","phase":"PHASE3","title":"Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)","status":"TERMINATED","sponsor":"Fundación Lindavista del Corazón AC","startDate":"2008-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT01004237","phase":"PHASE4","title":"Additive Effects of Pravastatin and Valsartan","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2009-11","conditions":"Hypertension, High Cholesterol","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pravastatin, valsartan, pravastatin+valsartan","genericName":"pravastatin, valsartan, pravastatin+valsartan","companyName":"Gachon University Gil Medical Center","companyId":"gachon-university-gil-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pravastatin inhibits HMG-CoA reductase to lower cholesterol, while valsartan blocks angiotensin II receptors to reduce blood pressure; the combination addresses both lipid and hypertension management. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both statin and ARB therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}